MY186475A - Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder - Google Patents
Pyridazine derivatives for use in the prevention or treatment of an ataxic disorderInfo
- Publication number
- MY186475A MY186475A MYPI2016703081A MYPI2016703081A MY186475A MY 186475 A MY186475 A MY 186475A MY PI2016703081 A MYPI2016703081 A MY PI2016703081A MY PI2016703081 A MYPI2016703081 A MY PI2016703081A MY 186475 A MY186475 A MY 186475A
- Authority
- MY
- Malaysia
- Prior art keywords
- prevention
- treatment
- pyridazine derivatives
- ataxic disorder
- ataxic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1403944.0A GB201403944D0 (en) | 2014-03-06 | 2014-03-06 | New use |
PCT/GB2015/050654 WO2015132608A1 (en) | 2014-03-06 | 2015-03-06 | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
MY186475A true MY186475A (en) | 2021-07-22 |
Family
ID=50554599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI2016703081A MY186475A (en) | 2014-03-06 | 2015-03-06 | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder |
Country Status (31)
Country | Link |
---|---|
US (1) | US20170014407A1 (de) |
EP (1) | EP3113778B1 (de) |
JP (1) | JP6510549B2 (de) |
KR (1) | KR20160126081A (de) |
CN (1) | CN106102743A (de) |
AU (1) | AU2015225954B2 (de) |
CA (1) | CA2940342A1 (de) |
CL (1) | CL2016002151A1 (de) |
CY (1) | CY1120573T1 (de) |
DK (1) | DK3113778T3 (de) |
EA (1) | EA036438B1 (de) |
ES (1) | ES2676905T3 (de) |
GB (1) | GB201403944D0 (de) |
GE (1) | GEP20196984B (de) |
HR (1) | HRP20181082T1 (de) |
IL (1) | IL247435A0 (de) |
LT (1) | LT3113778T (de) |
MA (1) | MA39315A1 (de) |
MX (1) | MX2016010524A (de) |
MY (1) | MY186475A (de) |
PH (1) | PH12016501751A1 (de) |
PL (1) | PL3113778T3 (de) |
PT (1) | PT3113778T (de) |
RS (1) | RS57594B1 (de) |
SG (1) | SG11201607106YA (de) |
SI (1) | SI3113778T1 (de) |
TR (1) | TR201809537T4 (de) |
TW (1) | TW201534591A (de) |
UA (1) | UA123352C2 (de) |
WO (1) | WO2015132608A1 (de) |
ZA (1) | ZA201604611B (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201222711D0 (en) | 2012-12-17 | 2013-01-30 | Takeda Pharmaceutical | Novel compounds |
CN111018790B (zh) | 2014-04-29 | 2023-09-19 | Fmc公司 | 哒嗪酮除草剂 |
TWI785022B (zh) | 2017-03-28 | 2022-12-01 | 美商富曼西公司 | 新穎噠嗪酮類除草劑 |
CN111315725B (zh) | 2017-06-30 | 2023-09-01 | Fmc公司 | 作为除草剂的4-(3,4-二氢萘-1-基或2h-色烯-4-基)-5-羟基-2h-哒嗪-3-酮 |
CN112569217B (zh) * | 2019-09-30 | 2022-04-22 | 厦门大学 | 戊酸衍生物在治疗遗传性小脑共济失调中的应用 |
JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
WO2022187127A1 (en) | 2021-03-01 | 2022-09-09 | Takeda Pharmaceutical Company Limited | Use of luvadaxistat for the treatment of cognitive impairment |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2262322T3 (es) * | 1998-06-10 | 2006-11-16 | Meiji Seika Kaisha, Ltd. | Tratamiento de la degenaracion espinocereberal y comoposiciones utiles para el tratamiento de degeneracion espinocerebelar. |
WO2003047558A2 (en) * | 2001-12-03 | 2003-06-12 | Genset S.A. | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors |
JO3115B1 (ar) * | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
-
2014
- 2014-03-06 GB GBGB1403944.0A patent/GB201403944D0/en not_active Ceased
-
2015
- 2015-03-05 TW TW104106995A patent/TW201534591A/zh unknown
- 2015-03-06 RS RS20180927A patent/RS57594B1/sr unknown
- 2015-03-06 CN CN201580012352.1A patent/CN106102743A/zh active Pending
- 2015-03-06 DK DK15709324.6T patent/DK3113778T3/en active
- 2015-03-06 SI SI201530291T patent/SI3113778T1/en unknown
- 2015-03-06 TR TR2018/09537T patent/TR201809537T4/tr unknown
- 2015-03-06 LT LTEP15709324.6T patent/LT3113778T/lt unknown
- 2015-03-06 US US15/123,796 patent/US20170014407A1/en not_active Abandoned
- 2015-03-06 UA UAA201608758A patent/UA123352C2/uk unknown
- 2015-03-06 ES ES15709324.6T patent/ES2676905T3/es active Active
- 2015-03-06 JP JP2016555645A patent/JP6510549B2/ja not_active Expired - Fee Related
- 2015-03-06 GE GEAP201514284A patent/GEP20196984B/en unknown
- 2015-03-06 WO PCT/GB2015/050654 patent/WO2015132608A1/en active Application Filing
- 2015-03-06 EA EA201691566A patent/EA036438B1/ru unknown
- 2015-03-06 EP EP15709324.6A patent/EP3113778B1/de active Active
- 2015-03-06 PT PT157093246T patent/PT3113778T/pt unknown
- 2015-03-06 MX MX2016010524A patent/MX2016010524A/es unknown
- 2015-03-06 CA CA2940342A patent/CA2940342A1/en not_active Abandoned
- 2015-03-06 SG SG11201607106YA patent/SG11201607106YA/en unknown
- 2015-03-06 MY MYPI2016703081A patent/MY186475A/en unknown
- 2015-03-06 AU AU2015225954A patent/AU2015225954B2/en not_active Ceased
- 2015-03-06 KR KR1020167027639A patent/KR20160126081A/ko unknown
- 2015-03-06 PL PL15709324T patent/PL3113778T3/pl unknown
- 2015-03-06 MA MA39315A patent/MA39315A1/fr unknown
-
2016
- 2016-07-06 ZA ZA2016/04611A patent/ZA201604611B/en unknown
- 2016-08-23 IL IL247435A patent/IL247435A0/en active IP Right Grant
- 2016-08-25 CL CL2016002151A patent/CL2016002151A1/es unknown
- 2016-09-06 PH PH12016501751A patent/PH12016501751A1/en unknown
-
2018
- 2018-07-10 HR HRP20181082TT patent/HRP20181082T1/hr unknown
- 2018-08-10 CY CY20181100843T patent/CY1120573T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
CL2017001566A1 (es) | Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales. | |
TW201613872A (en) | IRAK4 inhibiting agents | |
MD20170016A2 (ro) | Compuşi aminopirimidinici ca inhibitori JAK | |
MX2016006432A (es) | Tetrahidro-benzodiazepinonas. | |
MX2016011992A (es) | Derivados de piperidina-diona. | |
PH12016501751A1 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
PH12015501588A1 (en) | Compounds and methods for treating bacterial infections | |
MX2018004664A (es) | Antagonistas de ep4. | |
PH12017501071A1 (en) | Dihydropyrimidin-2-one compounds and medical use thereof | |
MX2017004655A (es) | Compuestos de hidroxil purinas y aplicaciones de estos. | |
EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
JOP20190163B1 (ar) | منشط nrf2 | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
EA201791099A1 (ru) | Хинолин карбоксамиды для применения в лечении лейкоза | |
PH12015500399A1 (en) | Azaindolines | |
PH12016502235A1 (en) | Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine | |
HK1251476A1 (zh) | 用於治療癌症的氨基硫羥酸酯化合物或其藥學上可接受的鹽 | |
SG10201903630UA (en) | Iminosugars useful for the treatment of viral diseases | |
MX2018002193A (es) | Metodo de uso de quinoxalinilo-piperazinamida. | |
MX2017005669A (es) | Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos. |